BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 9829586)

  • 21. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
    Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD
    Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy.
    Janevik-Ivanovska E; Gautherot E; Hillairet de Boisferon M; Cohen M; Milhaud G; Tartar A; Rostene W; Barbet J; Gruaz-Guyon A
    Bioconjug Chem; 1997; 8(4):526-33. PubMed ID: 9258451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
    Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
    Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens.
    Manetti C; Rouvier E; Gautherot E; Loucif E; Barbet J; Le Doussal JM
    Int J Cancer; 1997 Jun; 71(6):1000-9. PubMed ID: 9185704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
    Buchegger F; Pfister C; Fournier K; Prevel F; Schreyer M; Carrel S; Mach JP
    J Clin Invest; 1989 May; 83(5):1449-56. PubMed ID: 2708519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
    Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
    Sharkey RM; Motta-Hennessy C; Pawlyk D; Siegel JA; Goldenberg DM
    Cancer Res; 1990 Apr; 50(8):2330-6. PubMed ID: 2180566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
    Sharkey RM; Cardillo TM; Rossi EA; Chang CH; Karacay H; McBride WJ; Hansen HJ; Horak ID; Goldenberg DM
    Nat Med; 2005 Nov; 11(11):1250-5. PubMed ID: 16258537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody.
    Rauscher A; Frindel M; Maurel C; Maillasson M; Le Saëc P; Rajerison H; Gestin JF; Barbet J; Faivre-Chauvet A; Mougin-Degraef M
    Nucl Med Biol; 2014 May; 41 Suppl():e66-74. PubMed ID: 24485990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
    Boskovitz A; Akabani GH; Pegram CN; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2004 Apr; 31(3):345-55. PubMed ID: 15028247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.